Company registration number 15090603 (England and Wales)
VR PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
PAGES FOR FILING WITH REGISTRAR
VR PHARMA LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
VR PHARMA LIMITED
BALANCE SHEET
AS AT
31 JANUARY 2026
31 January 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Tangible assets
3
99,868
-
0
Current assets
Stocks
31,276
-
Debtors
4
42,161
-
0
Cash at bank and in hand
70,176
2
143,613
2
Creditors: amounts falling due within one year
5
(190,648)
-
0
Net current (liabilities)/assets
(47,035)
2
Total assets less current liabilities
52,833
2
Creditors: amounts falling due after more than one year
6
(92,025)
-
0
Provisions for liabilities
(24,967)
-
Net (liabilities)/assets
(64,159)
2
Capital and reserves
Called up share capital
2
2
Profit and loss reserves
(64,161)
-
0
Total equity
(64,159)
2
VR PHARMA LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 JANUARY 2026
31 January 2026
- 2 -

For the financial year ended 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 6 July 2026 and are signed on its behalf by:
Mr V Patel
Director
Company registration number 15090603 (England and Wales)
VR PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
- 3 -
1
Accounting policies
Company information

VR Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is 14 Merton Road, Harrow, England, HA2 0AB.

1.1
Reporting period

The financial statements are prepared for a period of 12 months. As this the first year of trading there are no comparatives available.

1.2
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.3
Going concern

The company has net current liabilities of £true 47,035 and net liabilities of £64,159. The directors has confirmed they will support the Company to meet its liabilities and obligations for at least twelve months from the date of approval of these financial statements.

For this reason, the directors continue to adopt the going concern basis in preparing the financial statements.

1.4
Revenue

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
15% on reducing balance
Computers
25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

VR PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 4 -
1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

VR PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 5 -
1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
7
0
3
Tangible fixed assets
Fixtures and fittings
Computers
Total
£
£
£
Cost
At 1 February 2025
-
0
-
0
-
0
Additions
115,895
1,810
117,705
At 31 January 2026
115,895
1,810
117,705
Depreciation and impairment
At 1 February 2025
-
0
-
0
-
0
Depreciation charged in the year
17,384
453
17,837
At 31 January 2026
17,384
453
17,837
Carrying amount
At 31 January 2026
98,511
1,357
99,868
At 31 January 2025
-
0
-
0
-
0
4
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
31,868
-
0
Other debtors
6,161
-
0
Prepayments and accrued income
4,132
-
0
42,161
-
VR PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 6 -
5
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
65,681
-
0
Taxation and social security
1,374
-
0
Other creditors
123,593
-
0
190,648
-
0
6
Creditors: amounts falling due after more than one year
2026
2025
£
£
Other creditors
92,025
-
0
2026-01-31 2025-02-01 false false false 06 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mrs R Patel Mr V Patel 15090603 2025-02-01 2026-01-31 15090603 2026-01-31 15090603 2025-01-31 15090603 core:FurnitureFittings 2026-01-31 15090603 core:ComputerEquipment 2026-01-31 15090603 core:FurnitureFittings 2025-01-31 15090603 core:ComputerEquipment 2025-01-31 15090603 core:CurrentFinancialInstruments core:WithinOneYear 2026-01-31 15090603 core:CurrentFinancialInstruments core:WithinOneYear 2025-01-31 15090603 core:Non-currentFinancialInstruments core:AfterOneYear 2026-01-31 15090603 core:Non-currentFinancialInstruments core:AfterOneYear 2025-01-31 15090603 core:CurrentFinancialInstruments 2026-01-31 15090603 core:CurrentFinancialInstruments 2025-01-31 15090603 core:ShareCapital 2026-01-31 15090603 core:ShareCapital 2025-01-31 15090603 core:RetainedEarningsAccumulatedLosses 2026-01-31 15090603 core:RetainedEarningsAccumulatedLosses 2025-01-31 15090603 bus:Director2 2025-02-01 2026-01-31 15090603 core:FurnitureFittings 2025-02-01 2026-01-31 15090603 core:ComputerEquipment 2025-02-01 2026-01-31 15090603 2024-09-01 2025-01-31 15090603 core:FurnitureFittings 2025-01-31 15090603 core:ComputerEquipment 2025-01-31 15090603 2025-01-31 15090603 core:Non-currentFinancialInstruments 2026-01-31 15090603 core:Non-currentFinancialInstruments 2025-01-31 15090603 bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 15090603 bus:SmallCompaniesRegimeForAccounts 2025-02-01 2026-01-31 15090603 bus:FRS102 2025-02-01 2026-01-31 15090603 bus:AuditExemptWithAccountantsReport 2025-02-01 2026-01-31 15090603 bus:Director1 2025-02-01 2026-01-31 15090603 bus:FullAccounts 2025-02-01 2026-01-31 xbrli:pure xbrli:shares iso4217:GBP